Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries
Impact of Multimodal Analgesia and ERAS Protocol on Length of Hospital Stay After Laparoscopic Gynecological Surgeries: A Randomized Control Trial
1 other identifier
interventional
98
1 country
1
Brief Summary
The goal of this clinical trial is to determine the length of hospital stay in patients using multimodal analgesia with or without ERAS protocol scheduled for elective laparoscopic gynecological surgeries
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Aug 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 24, 2025
CompletedFirst Posted
Study publicly available on registry
August 11, 2025
CompletedStudy Start
First participant enrolled
August 20, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
February 17, 2026
February 1, 2026
12 months
July 24, 2025
February 12, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Length of hospital stay
Post-operative length of hospital stay, measured in hours from the patient's arrival in the recovery room until 72 hours after surgery.
From arrival in the recovery room post-surgery until 72 hours after surgery.
Secondary Outcomes (3)
Postoperative pain score
4 hours, 8 hours, 12 hours, 24 hours, 48 hours & 72 hours postoperatively
Amount of opioid used in patient controlled analgesia
12 hours postoperatively.
Patient satisfaction Score
24 hours after the operation
Study Arms (2)
Group C
ACTIVE COMPARATORGroup E
EXPERIMENTALInterventions
Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.
Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg
Eligibility Criteria
You may qualify if:
- ASA physical status I, II, and III
- Patients scheduled for elective laparoscopic gynecological surgeries
You may not qualify if:
- Refusal to participate
- History of allergy or contraindication to study drugs
- Patients in which procedure converted to open surgery
- Diagnostic laparoscopic procedures
- Patients with a history of severe anxiety or depression
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aga Khan University, Karachi, Pakistan
Karachi, Sindh, Pakistan
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 24, 2025
First Posted
August 11, 2025
Study Start
August 20, 2025
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
November 1, 2026
Last Updated
February 17, 2026
Record last verified: 2026-02